Boceprevir: A novel NS3/4 protease inhibitor for the treatment of hepatitis C

Pharmacotherapy

Volumn 32, Issue 2, 2012, Pages 173-190

  Klibanov, Olga M ^a   Vickery, Stephen B ^a   Olin, Jacqueline L ^a   Smith, Lisa S ^a   Williams, Shannon H ^a  

^a WINGATE UNIVERSITY   (United States)

Author keywords

Boceprevir; Hepatitis C; NS3 4 protease inhibitors

Indexed keywords

BOCEPREVIR; BUPRENORPHINE PLUS NALOXONE; DIFLUNISAL; DROSPIRENONE; EFAVIRENZ; IBUPROFEN; INTERLEUKIN 28B; KETOCONAZOLE; METHADONE; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PLACEBO; RIBAVIRIN; RITONAVIR; TENOFOVIR;

ANEMIA; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHILL; CHOLELITHIASIS; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FATIGUE; GENE; HEADACHE; HEART INFARCTION; HEMATOLOGIC DISEASE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERLEUKIN 28B GENE; LIVER CANCER; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NEUTROPENIA; RIGOR; SEPSIS; VIRUS RESISTANCE;

CLINICAL TRIALS AS TOPIC; HEPATITIS C; HUMANS; PROLINE; PROTEASE INHIBITORS; TREATMENT OUTCOME; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84864592321     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/PHAR.1046     Document Type: Article

References (61)

1. World Health Organization. Health topics: hepatitis. Available from http://www.who.int/topics/hepatitis/en/. Accessed March 21, 2011.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Int Med 2006; 144:705-14.
3. National Institutes of Health. National Institutes of Health consensus development conference statement: management of hepatitis C: June 10-12, 2002. Hepatology 2002;36:S3-20.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa- 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
7. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006;131:1040-8.
8. Chung RT, Andersen J, Voberding P, et al. Peginterferon alfa- 2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in coinfected persons (ACTG 5071). N Engl J Med 2004;351:451-9.
9. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al., for the APRICOT Study Group. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004;351:438-50.
10. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa- 2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial (RIBAVIC). JAMA 2004;292:2839-48.
11. McHutchison JG, Poynard T, Pianko S, et al. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 2000;119:1317-23.
12. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites. N Engl J Med 2004;350:2265-71.
13. Cheng WSC, Roberts S, Weltman M, et al. Efficacy and safety of peginterferon alfa-2a 360 lg/week in combination with ribavirin in hepatitis C genotype 1 patients with cirrhosis: analysis from the chariot study. Presented at the 44th annual meeting of the European Association for the Study of the Liver, Copenhagen, Denmark, April 22-26, 2009.
14. U.S. Food and Drug Administration. FDA approves Victrelis for hepatitis C, May 13, 2011. Available from http://www.fda. gov/NewsEvents/Newsroom/ PressAnnouncements/ucm255390.
15. Chevaliez S, Pawlotsky J. HCV genome and lifecycle. In: Tan SL, ed. Hepatitis C viruses: genomes and molecular biology. Norfolk, UK: Horizon Bioscience, 2006:1-43.
16. Malcolm BA, Liu R, Lahser F, et al. SCH 503034, a mechanism- based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006;50:1013-20.
17. Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005;436:967-72.
18. Foster GR. Interferons in host defense. Semin Liver Dis 1996;17:287-95.
19. Lau JYN, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002;35:1002-9.
20. Merck & Co. Victrellis (boceprevir) product information. Whitehouse Station, NJ: Merck & Co, 2011.
21. Ghosal A, Yuan Y, Tong W, et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 2011;39:510-21.
22. Kempf DJ, Klein C, Chen HJ, et al. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir Chem Chemother 2007;18:163-7.
23. Kasserra C, Hughes E, Treitel M, Gupta S, O'Mara E. Clinical pharmacology of BOC: metabolism, excretion, and drug-drug interactions. Presented at the 18th conference on retroviruses and opportunistic infections, Boston, MA, February 27-March 2, 2011.
24. Sarrazin C, Rouzier R, Wagner F, et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferonalfa- 2b for genotype 1 nonresponders. Gastroenterology 2007;132:1270-8.
25. Silva M, Kasserra C, Gupta S, Treitel M, Hughes E, O'Mara E. Antiviral activity of boceprevir monotherapy in treatment- naïve subjects with chronic hepatitis C genotype 2/3. Presented at the 21st conference of the Asian Pacific Association for the Study of the Liver, Bangkok, Thailand, February 17- 20, 2011.
26. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomized, multicenter phase II trial. Lancet 2010;376:705-16.
27. Schiff E, Poordad FF, Jacobson IM, et al. Role of interferon response during re-treatment of null responders with boceprevir combination therapy: results of phase II trial [abstract]. Gastroenterology 2008;134:A-755.
28. Schiff E, Poordad F, Jacobson I, et al. Boceprevir (B) combination therapy in null responders (NR): response dependent on interferon responsiveness [abstract]. J Hepatol 2008;48:S46.
29. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
30. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infections. N Engl J Med 2011;364:1207-17.
31. Thibeault D, Bousquet C, Gingras R, et al. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J Virol 2004;78:7352-9.
32. Reiser M, Hinrichsen H, Benhamou Y, et al. Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology 2005;41: 832-5.
33. Foster GR, Hezode C, Bronowicki J-P, et al. Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naïve genotype 2 and 3 hepatitis-C patients: final results of study C209. Presented at the 45th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 14-18, 2010.
34. Benhamou Y, Moussalli J, Ratziu V, et al. Activity of telaprevir monotherapy or in combination with peginterferon-alfa-2a and ribavirin in treatment-naïve genotype 4 hepatitis-C patients: final results of study C210. Presented at the 61st annual meeting of the American Association for the Study of Liver Diseases, Boston, MA, October 29-November 2, 2010.
35. Vierling JM, Ralston R, Lawitz E, et al. Long-term outcomes following combination treatment with boceprevir plus pegintron/ribavirin (P/R) in patients with chronic hepatitis C, genotype 1 (CHC-G1). Presented at the 45th annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 14-18, 2010.
36. Vierling JM, Lawitz EJ, Poordad F, et al. Four-week therapy with peginterferon alfa-2b/ribavirin effectively predicts sustained virologic response in treatment-naïve and previoustreatment- failure patients with HCV-1 treated with boceprevir plus peginterferon alfa-2b/ribavirin. Presented at the 46th annual meeting of the European Association for the Study of the Liver, Berlin, Germany, March 30-April 3, 2011.
37. Manns MP, Poordad F, Bacon BR, et al. Response-guided therapy with boceprevir plus peginterferon alfa-2b/ribavirin reduces duration in naïve and peginterferon alfa-2b/ribavirin previous-treatment failure patients with HCV genotype 1. Presented at the 46th annual meeting of the European Association for the Study of the Liver, Berlin, Germany, March 30-April 3, 2011.
38. Bruno S, Vierling JM, Esteban R, et al. Boceprevir in addition to standard of care enhanced SVR in hepatitis c virus (HCV) genotype-1 with advanced fibrosis/cirrhosis: subgroup analysis of SPRINT-2 and RESPOND-2 studies. Presented at the 46th annual meeting of the European Association for the Study of the Liver, Berlin, Germany, March 30-April 3, 2011.
39. Poordad F, Bronowicki JP, Gordon SC, et al. IL28B polymorphism predicts virologic response in patients with hepatitis c genotype 1 treated with boceprevir (BOC) combination therapy. Presented at the 46th annual meeting of the European Association for the Study of the Liver, Berlin, Germany, March 30-April 3, 2011.
40. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
41. Asselah T, Estrabaud E, Bieche I, et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 2010;30:1259-69.
42. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008;48:1769-78.
43. Franco S, Bellido R, Aparicio E, et al. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors in HIV-1/HCV co-infected and HCV mono-infected patients. Presented at the 17th conference on retroviruses and opportunistic infections, Boston, MA, February 27-March 2, 2011.
44. Curry S, Qiu P, Tong X. Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alfa-2b using TaqMan mismatch amplification mutation assay. J Virol Methods 2008;153:1256-62.
45. Zeuzem S, Barnard RJ, Howe JA, et al. Boceprevir resistanceassociated variants (RAVS) are observed more frequently in HCV (GT1)-infected patients with poor response to peginterferon alpha-2b/ribavirin. Presented at the 46th annual meeting of the European Association for the Study of the Liver, Berlin, Germany, March 30-April 3, 2011.
46. Tong X, Chase R, Skelton A, et al. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006;70:28-38.
47. Barnard R, Howe J, Graham D, et al. Durability of response and rate of reemergence of wild type at BOC resistance-associated variant loci in genotype-1a and -1b patients: interim analysis of long-term follow-up of patients treated with BOC+pegIFN/RBV. Presented at the 17th conference on retroviruses and opportunistic infections, San Francisco, CA, February 16-19, 2010.
48. Lin C, Gates CA, Rao BG, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J Biol Chem 2005;280: 36784-91.
49. Mo H, Lu L, Pilot-Matias T, et al. Mutations conferring resistance to a potent hepatitis C (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother 2005;49:4305-14.
50. Flint M, Mullen S, Deatly AM, et al. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034). Antimicrob Agents Chemother 2009;53:401-11.
51. Centers for Disease Control and Prevention. Viral hepatitis scientific information. Available from http://www.cdc.gov/hepatitis/Populations/HIV.htm. Accessed March 25, 2011.
52. Sherman KE, Rouster SD, Chung RT, Rajiicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the U.S. adult AIDS clinical trials group. Clin Infect Dis 2002;34:831-73.
53. Radboud University. Pharmacokinetic study of the HCV protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir (OPAL). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT01288417?term=boceprevir&rank=6. Accessed July 21, 2011.
54. Schering-Plough. A study to evaluate the pharmacokinetic effect of SCH 503034 (boceprevir) on methadone or buprenorphine/naloxone plasma concentrations (P08123). ClinicalTrials. gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/NCT01396005? term=boceprevir&rank=1. Accessed July 21, 2011.
55. DeSilva KE, Le Flore DB, Marston BJ, Rimland D. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS 2001;15:1281-5.
56. Gutierrez MM, Rosenberg J, Abramowitz W. An evaluation of the potential for pharmacokinetic interaction between escita- lopram and the cytochrome P450 3A4 inhibitor ritonavir. Clin Ther 2003;25:1200-10.
57. Penzak SR, Hon YY, Lawhorn WD, et al. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers. J Clin Psychopharmacol 2002;22:366-70.
58. van der Lee MJ, Blenke AAM, Rongen GA, et al. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. Antimicrob Agents Chemother 2007;51:4098-104.
59. Schering-Plough. A phase 2b, safety and efficacy study of boceprevir in patients coinfected with HIV and hepatitis C (P05411 AM4). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http:// clinicaltrials.gov/ct2/show/NCT00959699?term=boceprevir&rank=3. Accessed July 21, 2011.
60. French National Agency for Research on AIDS and Viral Hepatitis. Boceprevir in HIV-HCV coinfected patients who have failed to a previous therapy with peg-interferon/ribavirin (BocepreVIH). ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available from http://clinicaltrials.gov/ct2/show/ NCT01335529? term=boceprevir&rank=13. Accessed July 21, 2011.
61. Vertex Pharmaceuticals Inc. Incivek (telaprevir) product information. Cambridge, MA: Vertex Pharmaceuticals Inc, 2011.